There were 285 new cases of measles in the U.S. in 2024. Measles, also known as rubeola, is an infectious disease that is highly contagious and affects mostly children. Common symptoms of measles include fever, runny nose, sore throat, cough, and a rash. Although death rates from measles have decreased around the world, it is still responsible for around 81,000 deaths worldwide per year. Measles vaccination The main reason for the decrease in measles cases and deaths is due to high vaccination rates. The widely used MMR vaccine protects against measles, mumps, and rubella and is safe and effective. In 2023, around 91 percent of adolescents in the U.S. aged 13 to 17 years had received an MMR vaccination. However, in recent years there has been a rise in measles cases in many parts of the world due to vaccine hesitancy. Vaccine hesitancy Vaccine hesitancy refers to a refusal or reluctance to have children vaccinated, despite the overwhelming evidence that vaccines are safe and effective. This hesitancy comes from a misunderstanding of the ingredients in vaccines and how they work, a mistrust of doctors and pharmaceutical companies, and belief in the unfounded associations of vaccines with other diseases and disorders.

The measles market is projected to reach a value of USD xxx million by 2033, exhibiting a CAGR of XX% during the forecast period. The market growth is driven by increasing immunization rates, rising awareness about the disease, and government initiatives to control measles outbreaks. The rising incidence of measles in various parts of the world, particularly in developing countries, is creating a significant demand for effective vaccines. Additionally, the increasing use of combination vaccines that protect against multiple diseases, including measles, is contributing to market growth. The market for measles vaccine products is segmented based on application and type. The major application segments include pediatric and adult vaccinations. The pediatric segment currently dominates the market, as measles is primarily a childhood disease. In terms of types, live attenuated vaccines are the most widely used, and they dominate the market share. Other types of measles vaccines include inactivated vaccines. geographically, the global measles market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America and Europe currently hold the largest market share due to high vaccination rates and well-established healthcare systems. However, the Asia Pacific region is expected to witness significant growth during the forecast period, owing to the increasing incidence of measles in developing countries and the expansion of vaccination programs.

The global market for Measles, Mumps, and Rubella (MMR) Virus Vaccine Live is experiencing robust growth, driven by increasing immunization programs globally and a rising awareness of the importance of preventative healthcare. The market, currently valued at approximately $2.5 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of around 7% from 2025 to 2033. This growth is fueled by several factors, including government initiatives promoting vaccination, expanding healthcare infrastructure in developing nations, and a persistent threat of MMR outbreaks, particularly in regions with low vaccination coverage. The segment for pediatric vaccines is expected to dominate, reflecting higher susceptibility in children. However, the adult segment is also demonstrating substantial growth due to increasing awareness of MMR susceptibility in adults and the availability of effective booster shots. Geographically, North America and Europe currently hold significant market shares due to high vaccination rates and well-established healthcare systems. However, the Asia-Pacific region is expected to exhibit the fastest growth in the forecast period, driven by rising disposable incomes, improving healthcare infrastructure, and increasing government investments in public health initiatives. Major market players like Merck, Shanghai Institute of Biological Products, and Beijing Tiantan Biological Products are actively engaged in research and development to improve vaccine efficacy, safety, and accessibility. Despite significant growth potential, the market faces challenges, including vaccine hesitancy in certain populations, logistical difficulties in vaccine distribution, and the emergence of vaccine-resistant strains. Further growth will depend on sustained investment in public health infrastructure and innovative approaches to vaccination campaigns, such as the integration of technology and data-driven solutions to enhance surveillance and targeting of vaccination efforts. The successful implementation of comprehensive immunization programs in underserved regions will significantly contribute to market expansion. Ongoing research and development efforts toward improved vaccine formulations, including those targeting specific MMR variants, will also play a pivotal role in shaping market trajectory and addressing emerging challenges. Competition among key players is expected to remain intense, with ongoing focus on improving product efficacy, reducing costs, and expanding geographical reach. The regulatory landscape for vaccine approvals and distribution will also be a crucial factor influencing the market’s trajectory.

As of 2017, around 91.5 percent of children in the U.S. aged 19 to 35 months had been vaccinated against measles, mumps and rubella (MMR). The MMR vaccine is widely used around the world and is recommended by the Centers for Disease Control and Prevention (CDC) for adults who don’t have immunity and all children.

Measles

The number of cases of measles in the United States has dropped significantly since the introduction of the MMR vaccination. However, there has been a recent increase in measles cases, due to the growth of the vaccine hesitancy movement. Despite claims from this movement, the MMR vaccine is safe and effective. One dose of the MMR vaccine is around 93 percent effective against measles, while two doses is 97 percent effective.

Mumps

The MMR vaccine has resulted in a similar decrease in the rate of mumps cases in the U.S. One dose of the MMR vaccine is 78 percent effective against mumps, while two doses is 88 percent effective. Although the MMR vaccine is safe and effective, like any medicine it can have side effects. Common side effects include fever, a mild rash and temporary joint pain and stiffness.